ReviewSeminars in respiratory and critical care medicine2015
Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options.
Review in Seminars in respiratory and critical care medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 150 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
150 citing papers in PubMed, 1 synthesis or guideline pooled it, 315 citations in OpenAlex.
- Systematic Review and Meta-Analysis of the Occurrence of ESKAPE Bacteria Group in Dogs, and the Related Zoonotic Risk in Animal-Assisted Therapy, and in Animal-Assisted Activity in the Health Context.International journal of environmental research and public health · 2020Pooled it
- Bacterial Lysis Observation Over Time Assay (BLOTS) for High-Throughput Isolation, Sequencing, and Characterization of Bacteriophages.Current protocols · 2026Article
- Distinct Epidemiology and Temporal Trends of Multidrug-Resistant Organisms in a Newly Established Hospital: A Five-Year Surveillance Study.Antibiotics (Basel, Switzerland) · 2026Article
- Article
- Antibiotic Resistance ofAnimals : an open access journal from MDPI · 2026Article
- Article
- Molecular Identification and Phenotypic Antimicrobial Resistance ofAntibiotics (Basel, Switzerland) · 2026Article
- Therapeutic Potential of Antimicrobial Peptide ScymicrosinProbiotics and antimicrobial proteins · 2026Article
- Retrospective Analysis of the Molecular Links Among Clustered Cases ofChina CDC weekly · 2026Article
- A Clinically Silent Resistance Phenotype That PromotesbioRxiv : the preprint server for biology · 2026Article
- Molecular Characterization and Clonal Analysis of Carbapenem-ResistantBioMed research international · 2026Article
- Lineage-Specific Associations between the Resistome and Mobilome across 10,500 Globally DistributedComputational and structural biotechnology journal · 2026Article
- Biofilm Formation in ClinicalBioMed research international · 2026Article
- Burden and Economic Impact of Antimicrobial Resistance inThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
- Impact of iron limitation on in vitro and in vivo activity of ceftazidime against A. baumannii.Diagnostic microbiology and infectious disease · 2025Article
- Antibiotic Resistance Patterns of Bacteria Involved in Colonization and/or Infection of Patients in Intensive Care Units in Northeastern Romania.Antibiotics (Basel, Switzerland) · 2025Article
- Clinical Analysis ofJournal of clinical medicine · 2025Article
- Contribution of RND superfamily multidrug efflux pumps AdeABC, AdeFGH, and AdeIJK to antimicrobial resistance and virulence factors in multidrug-resistantAntimicrobial agents and chemotherapy · 2025Article
- Distribution of carbapenemase-producing and colistin resistant Acinetobacter baumannii isolates in Batna hospitals, Algeria.BMC infectious diseases · 2025Article
- Matrine Restores Colistin Efficacy AgainstMolecules (Basel, Switzerland) · 2025Article
90 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
The first decade of the 20th century witnessed a surge in the incidence of infections due to several highly antimicrobial-resistant bacteria in hospitals worldwide. Acinetobacter baumannii is one such organism that turned from an occasional respiratory pathogen into a major nosocomial pathogen. An increasing number of A. baumannii genome sequences have broadened our understanding of the genetic makeup of these bacteria and highlighted the extent of horizontal transfer of DNA. Animal models of disease combined with bacterial mutagenesis have provided some valuable insights into mechanisms of A. baumannii pathogenesis. Bacterial factors known to be important for disease include outer membrane porins, surface structures including capsule and lipopolysaccharide, enzymes such as phospholipase D, iron acquisition systems, and regulatory proteins. A. baumannii has a propensity to accumulate resistance to various groups of antimicrobial agents. In particular, carbapenem resistance has become commonplace, accounting for the majority of A. baumannii strains in many hospitals today. Carbapenem-resistant strains are often resistant to all other routinely tested agents. Treatment of carbapenem-resistant A. baumannii infection therefore involves the use of combinations of last resort agents such as colistin and tigecycline, but the efficacy and safety of these approaches are yet to be defined. Antimicrobial-resistant A. baumannii has high potential to spread among ill patients in intensive care units. Early recognition and timely implementation of appropriate infection control measures is crucial in preventing outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.